X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (224) 224
pemetrexed (221) 221
humans (211) 211
guanine - analogs & derivatives (193) 193
ly231514 (175) 175
female (117) 117
chemotherapy (112) 112
glutamates - administration & dosage (102) 102
guanine - administration & dosage (102) 102
aged (100) 100
male (100) 100
middle aged (98) 98
index medicus (94) 94
multitargeted antifolate (92) 92
adult (83) 83
antineoplastic combined chemotherapy protocols - therapeutic use (83) 83
lung neoplasms - drug therapy (82) 82
multitargeted antifolate ly231514 (81) 81
cisplatin (76) 76
carcinoma, non-small-cell lung - drug therapy (71) 71
glutamates - therapeutic use (70) 70
guanine - therapeutic use (70) 70
thymidylate synthase (64) 64
treatment outcome (62) 62
glutamates - adverse effects (59) 59
guanine - adverse effects (59) 59
pharmacology & pharmacy (59) 59
gemcitabine (58) 58
disodium (57) 57
cancer (54) 54
cell lung-cancer (51) 51
antifolate (49) 49
combination (47) 47
glutamates - pharmacology (45) 45
guanine - pharmacology (45) 45
antineoplastic agents - therapeutic use (41) 41
deoxycytidine - analogs & derivatives (41) 41
lung neoplasms - pathology (38) 38
antineoplastic combined chemotherapy protocols - adverse effects (37) 37
aged, 80 and over (36) 36
malignant pleural mesothelioma (36) 36
trial (36) 36
respiratory system (35) 35
carcinoma (34) 34
continual reassessment method (34) 34
mta (34) 34
drug administration schedule (33) 33
neoplasms - drug therapy (33) 33
phase-ii trial (33) 33
antimetabolites, antineoplastic - therapeutic use (31) 31
cisplatin - administration & dosage (31) 31
deoxycytidine - administration & dosage (31) 31
neoplasm staging (31) 31
research (31) 31
solid tumors (31) 31
glutamates - pharmacokinetics (30) 30
guanine - pharmacokinetics (30) 30
phase-ii (30) 30
therapy (30) 30
carcinoma, non-small-cell lung - pathology (29) 29
dose-response relationship, drug (29) 29
lung cancer, non-small cell (28) 28
methotrexate (28) 28
animals (27) 27
antimitotic agents (26) 26
antineoplastic agents (26) 26
mta ly231514 (26) 26
mesothelioma - drug therapy (25) 25
alimta (24) 24
antineoplastic agents - pharmacology (24) 24
care and treatment (24) 24
drug therapy (24) 24
lung cancer (24) 24
non-small cell lung cancer (24) 24
toxicity (24) 24
clinical trials as topic (23) 23
hematology, oncology and palliative medicine (23) 23
survival rate (23) 23
antineoplastic agents - adverse effects (22) 22
antineoplastic combined chemotherapy protocols - administration & dosage (22) 22
carboplatin (22) 22
maximum tolerated dose (22) 22
clinical trials (21) 21
antimetabolites, antineoplastic - adverse effects (20) 20
medicine & public health (20) 20
pharmacology/toxicology (20) 20
cell line, tumor (19) 19
prognosis (19) 19
antimetabolites, antineoplastic - administration & dosage (18) 18
docetaxel (18) 18
folic acid (18) 18
folic-acid (18) 18
infusions, intravenous (18) 18
phase-i (18) 18
thymidylate synthase inhibitor (18) 18
acid (17) 17
breast neoplasms - drug therapy (17) 17
folic acid antagonists - pharmacology (17) 17
human tumor xenografts (17) 17
nsclc (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CLINICAL CANCER RESEARCH, ISSN 1078-0432, 12/2019, Volume 25, Issue 23, pp. 7175 - 7188
Purpose: Combination strategies leveraging chemotherapeutic agents and immunotherapy have held the promise as a method to improve benefit for patients with... 
APOPTOSIS | ACTIVATION | ONCOLOGY | T-CELL METABOLISM | METHOTREXATE | AMPK | CHECKPOINT | MTA | PD-1 | LY231514
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2003, Volume 21, Issue 8, pp. 1556 - 1561
Purpose: This phase II clinical study evaluated the efficacy of pemetrexed for the treatment of malignant pleural mesothelioma (MPM). Patients and Methods:... 
CELL LUNG-CANCER | LEUKEMIA GROUP-B | ONCOLOGY | CLINICAL-TRIALS | MULTITARGETED ANTIFOLATE LY231514 | MTA | DISODIUM | CHEMOTHERAPY
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2008, Volume 14, Issue 13, pp. 4206 - 4212
Purpose: The objective of this study was to evaluate the efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B-12 in... 
OF-LIFE QUESTIONNAIRE | TRIAL | ONCOLOGY | RANDOMIZED PHASE-III | I EVALUATION | CONTINUAL REASSESSMENT METHOD | MULTITARGETED ANTIFOLATE | JAPANESE PATIENTS | DISODIUM | CARCINOMA | LY231514
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 10/2018, Volume 59, Issue 10, pp. 1544 - 1550
Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the United States, and pemetrexed-based therapies are regularly used to treat... 
dexamethasone | METAANALYSIS | PROLIFERATION | imaging | CHEMOTHERAPY | GEMCITABINE | FLT | lung cancer | HETEROGENEITY | POSITRON-EMISSION-TOMOGRAPHY | GLUCOCORTICOID-RECEPTOR | RANDOMIZED PHASE-III | ANTIFOLATE LY231514 | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PET
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2012, Volume 7, Issue 5, pp. 833 - 840
Folate receptor alpha (FRα) and reduced folate carrier-1 (RFC1) regulate uptake of folate molecules inside the cell. FRα is a potential biomarker of tumors... 
Non−small-cell lung carcinoma | membrane transporter | Folate receptor alpha | Reduced folate carrier-1 | Epidermal growth factor receptor | Membrane transporter | Non-small-cell lung carcinoma | FARLETUZUMAB | THYMIDYLATE SYNTHASE | ANTIFOLATE | CHEMOTHERAPY | LY231514 | CARRIER | GROWTH-FACTOR RECEPTOR | ONCOLOGY | RESPIRATORY SYSTEM | GENE-EXPRESSION | CARCINOMA
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2019, Volume 121, pp. 64 - 73
Journal Article
by Qi, H and Wen, J and Li, L and Bai, R and Chen, L and Wang, D
Journal of Heterocyclic Chemistry, ISSN 0022-152X, 09/2015, Volume 52, Issue 5, pp. 1565 - 1569
An efficient synthetic method for the pemetrexed disodium has been developed using methyl 4‐iodobenzoate and 3‐buten‐1‐ol as starting materials via six steps.... 
ALIMTA | CHEMISTRY, ORGANIC | PHASE-II | ACID | CANCER | LY231514 | Antimitotic agents | Antineoplastic agents
Journal Article
ANTI-CANCER DRUGS, ISSN 0959-4973, 06/2016, Volume 27, Issue 5, pp. 439 - 446
The objectives of this single-center, open-label, phase II study were to evaluate (a) the feasibility and safety of neoadjuvant administration of pemetrexed... 
homocysteine | pemetrexed | reduced folates | MECHANISM | rectal cancer | ENZYME-INHIBITION | PHASE-III | METHYLMALONIC ACID | MULTITARGETED ANTIFOLATE | LY231514 | TRIAL | ONCOLOGY | COLORECTAL-CANCER | cystathionine | PHARMACOLOGY & PHARMACY | MEMBRANE-TRANSPORT
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 2014, Volume 15, Issue 19, pp. 8391 - 8394
Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed based salvage chemotherapy for treatment of patients with... 
Response rate | Pemetrexed chemotherapy | Metastatic colorectal cancer | pemetrexed chemotherapy | PLUS IRINOTECAN | ONCOLOGY | response rate | ANTIFOLATE | PHASE-II | LY231514 | CHEMOTHERAPY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 4, pp. 614 - 619
Journal Article
Journal of Cancer, ISSN 1837-9664, 2018, Volume 9, Issue 16, pp. 2910 - 2915
Background: We designed a single-arm, open-label phase II study to determine the efficacy and toxicity of pemetrexed monotherapy with vitamin supplementation... 
Pemetrexed | Colorectal cancer | Vitamin | PLACEBO | MULTICENTER | LEUCOVORIN | colorectal cancer | MULTITARGETED ANTIFOLATE | FLUOROURACIL | vitamin | LY231514 | CELL LUNG-CANCER | ONCOLOGY | DOUBLE-BLIND | IRINOTECAN | ERLOTINIB
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2007, Volume 2, Issue 5, pp. 397 - 401
In a recent large phase III study, previously treated patients with advanced non-small cell lung cancer who received pemetrexed demonstrated a survival time... 
Toxicity | Pemetrexed | Survival | Non-small cell lung cancer | toxicity | non-small cell lung cancer | TRIAL | pemetrexed | ONCOLOGY | RESPIRATORY SYSTEM | THYMIDYLATE SYNTHASE | survival | LY231514 MTA | ANTIFOLATE | CHEMOTHERAPY | FOLATE
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 11/2018, Volume 19, Issue 6, pp. 461 - 463
The administration of pemetrexed requires routine supplementation with vitamin B12 and folate, even if blood concentrations are normal, in order to mitigate... 
Non-small-cell lung cancer | Malignant pleural mesothelioma | Adverse events | Vitamin supplementation | Folate | EFFICACY | ANTIFOLATE | FOLIC-ACID | DOCETAXEL | CHEMOTHERAPY | LY231514 | CELL LUNG-CANCER | THERAPY | ONCOLOGY | NIVOLUMAB | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2014, Volume 9, Issue 5, p. e97888
Journal Article
Journal Article